Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
McKesson
McKinsey
Medtronic
Merck
Mallinckrodt

Generated: March 18, 2019

DrugPatentWatch Database Preview

Metuchen Pharms Company Profile

« Back to Dashboard

Summary for Metuchen Pharms
International Patents:53
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Metuchen Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-003 Apr 27, 2012 RX Yes Yes 7,501,409 ➤ Try a Free Trial Y ➤ Try a Free Trial
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-001 Apr 27, 2012 RX Yes No 7,501,409 ➤ Try a Free Trial Y ➤ Try a Free Trial
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-002 Apr 27, 2012 RX Yes No 6,656,935 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-003 Apr 27, 2012 RX Yes Yes 6,656,935 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-001 Apr 27, 2012 RX Yes No 6,656,935 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-002 Apr 27, 2012 RX Yes No 7,501,409 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for METUCHEN PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 50 mg, 100 mg and 200 mg ➤ Subscribe 2016-04-27

Supplementary Protection Certificates for Metuchen Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1219609 1390047-7 Sweden ➤ Try a Free Trial PRODUCT NAME: AVANAFIL; REG. NO/DATE: EU/1/13/841 20130621
1219609 92249 Luxembourg ➤ Try a Free Trial PRODUCT NAME: AVANAFIL
1219609 122013000096 Germany ➤ Try a Free Trial PRODUCT NAME: AVANAFIL UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/13/841 20130621
1219609 13C0050 France ➤ Try a Free Trial PRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: EU/1/13/841 20130621
1219609 476 Finland ➤ Try a Free Trial
1219609 2013/041 Ireland ➤ Try a Free Trial PRODUCT NAME: AVANAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/841 20130613
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Cipla
Chubb
Daiichi Sankyo
Merck
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.